CN106103445B - 作为cdk抑制剂的吡唑并[1,5-a]嘧啶-5,7-二胺化合物和它们的治疗用途 - Google Patents

作为cdk抑制剂的吡唑并[1,5-a]嘧啶-5,7-二胺化合物和它们的治疗用途 Download PDF

Info

Publication number
CN106103445B
CN106103445B CN201580011502.7A CN201580011502A CN106103445B CN 106103445 B CN106103445 B CN 106103445B CN 201580011502 A CN201580011502 A CN 201580011502A CN 106103445 B CN106103445 B CN 106103445B
Authority
CN
China
Prior art keywords
compound
compound according
mmol
independently
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580011502.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN106103445A (zh
Inventor
亚历山大·波恩德克
塞巴斯蒂安·克罗尔
安东尼·巴雷特
马修·富克特
布赖恩·斯拉弗
西马克·阿里
查尔斯·库姆斯
詹姆士·帕特里克·希德尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ip2 Ipo Innovation Co Ltd
Emory University
Original Assignee
Imperial Innovations Ltd
Cancer Research Technology Ltd
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Innovations Ltd, Cancer Research Technology Ltd, Emory University filed Critical Imperial Innovations Ltd
Publication of CN106103445A publication Critical patent/CN106103445A/zh
Application granted granted Critical
Publication of CN106103445B publication Critical patent/CN106103445B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201580011502.7A 2014-02-21 2015-02-20 作为cdk抑制剂的吡唑并[1,5-a]嘧啶-5,7-二胺化合物和它们的治疗用途 Active CN106103445B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1403093.6 2014-02-21
GB201403093A GB201403093D0 (en) 2014-02-21 2014-02-21 Therapeutic compounds and their use
PCT/GB2015/050494 WO2015124941A1 (en) 2014-02-21 2015-02-20 Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as cdk inhibitors and their therapeutic use

Publications (2)

Publication Number Publication Date
CN106103445A CN106103445A (zh) 2016-11-09
CN106103445B true CN106103445B (zh) 2019-08-09

Family

ID=50482596

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580011502.7A Active CN106103445B (zh) 2014-02-21 2015-02-20 作为cdk抑制剂的吡唑并[1,5-a]嘧啶-5,7-二胺化合物和它们的治疗用途

Country Status (23)

Country Link
US (4) US9932344B2 (enExample)
EP (1) EP3107914B8 (enExample)
JP (1) JP6498212B2 (enExample)
CN (1) CN106103445B (enExample)
AU (1) AU2015220560B2 (enExample)
BR (1) BR112016018633B1 (enExample)
CA (1) CA2939786C (enExample)
CY (1) CY1121588T1 (enExample)
DK (1) DK3107914T3 (enExample)
ES (1) ES2721268T3 (enExample)
GB (1) GB201403093D0 (enExample)
HR (1) HRP20190685T1 (enExample)
HU (1) HUE043122T2 (enExample)
LT (1) LT3107914T (enExample)
ME (1) ME03427B (enExample)
NZ (1) NZ724323A (enExample)
PL (1) PL3107914T3 (enExample)
PT (1) PT3107914T (enExample)
RS (1) RS58704B1 (enExample)
SI (1) SI3107914T1 (enExample)
SM (1) SMT201900266T1 (enExample)
TR (1) TR201905647T4 (enExample)
WO (1) WO2015124941A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2824118C1 (ru) * 2021-01-22 2024-08-06 Шанхай Хайян Фармасьютикал Текнолоджи Ко., Лтд. ЗАМЕЩЕННОЕ ПРОИЗВОДНОЕ ПИРАЗОЛ[1,5-a]ПИРИМИДИН-7-АМИНА, ЕГО КОМПОЗИЦИЯ И ФАРМАЦЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201403093D0 (en) 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use
CA2966164C (en) 2014-10-31 2023-10-17 Ube Industries, Ltd. Substituted dihydropyrrolopyrazole compound
US9994559B2 (en) 2014-12-17 2018-06-12 King's College London Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists
WO2016130920A2 (en) * 2015-02-13 2016-08-18 Dana-Farber Cancer Institute, Inc. Lrrk2 inhibitors and methods of making and using the same
EP3309163A4 (en) 2015-06-15 2019-01-09 UBE Industries, Ltd. SUBSTITUTED DIHYDROPYRROLO PYRAZOL DERIVATIVE
US20200123499A1 (en) 2015-12-02 2020-04-23 Massachusetts Institute Of Technology Method for efficient generation of neurons from non-neuronal cells
SG11201901747VA (en) 2016-08-31 2019-03-28 Agios Pharmaceuticals Inc Inhibitors of cellular metabolic processes
JP7216705B2 (ja) 2017-07-28 2023-02-02 ニンバス ラクシュミ， インコーポレイテッド Ｔｙｋ２阻害剤およびその使用方法
KR102700664B1 (ko) * 2017-08-07 2024-08-29 조인트 스탁 컴퍼니 “바이오케드” Cdk8/19 저해제로서 새로운 헤테로사이클릭 화합물
US20200197392A1 (en) * 2017-08-15 2020-06-25 The Brigham & Women's Hospital, Inc. Compositions and methods for treating tuberous sclerosis complex
GB201715194D0 (en) * 2017-09-20 2017-11-01 Carrick Therapeutics Ltd Compounds and their therapeutic use
TWI703149B (zh) * 2017-11-16 2020-09-01 美商美國禮來大藥廠 用於抑制cdk7之化合物
WO2019197549A1 (en) * 2018-04-11 2019-10-17 Qurient Co., Ltd. Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase
EP3787629A4 (en) 2018-05-02 2022-01-05 Kinnate Biopharma Inc. CYCLINE-DEPENDENT KINASE INHIBITORS
EP3813819A4 (en) 2018-06-29 2022-08-17 Kinnate Biopharma Inc. CYCLIN-DEPENDENT KINASE INHIBITORS
MY210039A (en) 2018-10-30 2025-08-22 Kronos Bio Inc Compounds, compositions, and methods for modulating cdk9 activity
EP3885347B1 (en) 2018-11-14 2023-11-22 UBE Corporation Dihydropyrrolopyrazole derivative
CN109860354B (zh) * 2018-12-28 2020-05-19 南京邮电大学 同质集成红外光子芯片及其制备方法
WO2020186196A1 (en) * 2019-03-13 2020-09-17 The Translational Genomics Research Institute Trisubstituted pyrazolo [1,5-a] pyrimidine compounds as cdk7 inhibitors
CN114269742B (zh) * 2019-07-10 2024-07-16 常州千红生化制药股份有限公司 作为治疗剂的4-(咪唑并[1,2-a]吡啶-3-基)-N-(吡啶基)嘧啶-2-胺的衍生物
WO2021087138A1 (en) * 2019-10-29 2021-05-06 Syros Pharmaceuticals, Inc. Methods of treating cancer in biomarker-identified patients with inhibitors of cyclin-dependent kinase 7 (cdk7)
GB201918541D0 (en) * 2019-12-16 2020-01-29 Carrick Therapeutics Ltd Therapeutic compounds and their use
CA3174507A1 (en) * 2020-03-06 2021-09-10 Bayer Aktiengesellschaft Imidazotriazines acting on cancer via inhibition of cdk12
US20230158159A1 (en) * 2020-04-24 2023-05-25 Massachusetts Institute Of Technology Chimeric degraders of cyclin-dependent kinase 9 and uses thereof
EP4282868B1 (en) * 2021-01-22 2026-03-04 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Substituted pyrazolo[1,5-a]pyrimidine-7-amine derivative, and compositions and medical use thereof
KR20240020735A (ko) 2021-05-07 2024-02-15 카이메라 쎄라퓨틱스 인코포레이티드 Cdk2 분해제 및 그 용도
GB202108572D0 (en) * 2021-06-16 2021-07-28 Carrick Therapeutics Ltd Therapeutic compounds and their use
WO2023001061A1 (en) * 2021-07-17 2023-01-26 Jingrui Biopharma Co., Ltd. Cdk7 selective inhibitors as anticancer agents
WO2023096922A1 (en) * 2021-11-24 2023-06-01 Kronos Bio, Inc. Polymorphic and salt forms of (ls,3s)-n1-(5-(pentan-3- yl)pyrazolo[l,5-a]pyrimidin-7-yl)cyclopentane-l,3-diamine
WO2024102447A1 (en) * 2022-11-10 2024-05-16 Emory University Uses of hydroimidazopyridopyrimidinone derivatives for managing aneurysms or other vascular conditions or diseases
EP4671245A1 (en) * 2023-02-20 2025-12-31 Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. HETEROAROMATIC CYCLIC COMPOUND SERVING AS A CDK7 KINASE INHIBITOR, ITS PREPARATION AND USE
WO2024175024A1 (zh) * 2023-02-21 2024-08-29 杭州德睿智药科技有限公司 作为CDKs抑制剂的新型并杂环类新化合物及其应用
TW202500147A (zh) 2023-06-27 2025-01-01 美商亞文納營運公司 雌激素受體降解劑與ｃｄｋ７抑制劑之組合
WO2025057087A1 (en) 2023-09-11 2025-03-20 Assia Chemical Industries Ltd. Solid state forms of samuraciclib
WO2025208104A1 (en) * 2024-03-29 2025-10-02 The Translational Genomics Research Institute Cdk7 inhibitors and methods of use thereof
WO2025208097A1 (en) * 2024-03-29 2025-10-02 The Translational Genomics Research Institute Cdk7 inhibitors and methods of use thereof
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087707A1 (en) * 2003-03-31 2004-10-14 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
WO2008151304A1 (en) * 2007-06-05 2008-12-11 Emory University Selective inhibitors for cyclin-dependent kinases
CN102762208A (zh) * 2009-12-04 2012-10-31 赛林药物股份有限公司 作为ck2抑制剂的吡唑嘧啶和相关杂环

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1246823A1 (en) 1999-12-28 2002-10-09 Pharmacopeia, Inc. Pyrimidine and triazine kinase inhibitors
EP1537116B1 (en) 2002-09-04 2010-06-02 Schering Corporation Pyrazolopyrimidines suitable for the treatment of cancer diseases
CA2513684A1 (en) 2003-01-31 2004-08-19 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
EP1599482A4 (en) 2003-02-28 2008-10-01 Teijin Pharma Ltd PYRAZOLO1,5-A PYRIMIDINE DERIVATIVES
JO2478B1 (en) 2003-06-19 2009-01-20 جانسين فارماسوتيكا ان. في. (Aminomethyl) -biperidine benzamides as 5 HT4 antagonists
CN101360499B (zh) * 2005-10-06 2015-10-07 默沙东公司 吡唑并[1,5-a]嘧啶衍生物在制备抑制蛋白激酶的药物中的用途
WO2012059932A1 (en) 2010-11-01 2012-05-10 Aurigene Discovery Technologies Limited 2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors
PL3409278T3 (pl) * 2011-07-21 2021-02-22 Sumitomo Pharma Oncology, Inc. Heterocykliczne inhibitory kinazy białkowej
EP2634190A1 (en) 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors
EP2634189A1 (en) 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhibitors
GB201403093D0 (en) 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087707A1 (en) * 2003-03-31 2004-10-14 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
WO2008151304A1 (en) * 2007-06-05 2008-12-11 Emory University Selective inhibitors for cyclin-dependent kinases
CN102762208A (zh) * 2009-12-04 2012-10-31 赛林药物股份有限公司 作为ck2抑制剂的吡唑嘧啶和相关杂环

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2824118C1 (ru) * 2021-01-22 2024-08-06 Шанхай Хайян Фармасьютикал Текнолоджи Ко., Лтд. ЗАМЕЩЕННОЕ ПРОИЗВОДНОЕ ПИРАЗОЛ[1,5-a]ПИРИМИДИН-7-АМИНА, ЕГО КОМПОЗИЦИЯ И ФАРМАЦЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ

Also Published As

Publication number Publication date
WO2015124941A1 (en) 2015-08-27
HUE043122T2 (hu) 2019-08-28
US20160362410A1 (en) 2016-12-15
JP2017506250A (ja) 2017-03-02
CA2939786A1 (en) 2015-08-27
US10927119B2 (en) 2021-02-23
RS58704B1 (sr) 2019-06-28
US20180273540A1 (en) 2018-09-27
PL3107914T3 (pl) 2019-09-30
BR112016018633A2 (enExample) 2017-08-08
BR112016018633B1 (pt) 2022-08-30
SI3107914T1 (sl) 2019-05-31
US20200055862A1 (en) 2020-02-20
DK3107914T3 (en) 2019-04-29
EP3107914B8 (en) 2019-07-17
US20210253583A1 (en) 2021-08-19
PT3107914T (pt) 2019-05-20
US9932344B2 (en) 2018-04-03
EP3107914A1 (en) 2016-12-28
CN106103445A (zh) 2016-11-09
TR201905647T4 (tr) 2019-05-21
ME03427B (me) 2020-01-20
ES2721268T3 (es) 2019-07-30
US10414772B2 (en) 2019-09-17
LT3107914T (lt) 2019-05-27
AU2015220560A1 (en) 2016-10-06
CA2939786C (en) 2022-03-08
CY1121588T1 (el) 2020-05-29
JP6498212B2 (ja) 2019-04-10
EP3107914B1 (en) 2019-01-30
US11566029B2 (en) 2023-01-31
NZ724323A (en) 2022-02-25
GB201403093D0 (en) 2014-04-09
SMT201900266T1 (it) 2019-07-11
AU2015220560B2 (en) 2019-05-16
HRP20190685T1 (hr) 2019-06-14

Similar Documents

Publication Publication Date Title
CN106103445B (zh) 作为cdk抑制剂的吡唑并[1,5-a]嘧啶-5,7-二胺化合物和它们的治疗用途
ES2359410T3 (es) Derivados de pirazolopirimidina como inhibidores de quinasas ciclina-dependientes.
JP5656976B2 (ja) ピロロトリアジン化合物
KR102559719B1 (ko) 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체 조절제 및 이의 용도
CN111566106B (zh) 作为cdk抑制剂的化合物
CN108366994B (zh) 新型Jak1选择性抑制剂及其用途
EP4072548A1 (en) Compositions and methods for substituted 7-(piperazin-1-yl)pyrazolo[1,5-a]pyrimidine analogs as inhibitors of kras
CN100376580C (zh) 作为细胞周期蛋白依赖性激酶抑制剂的吡唑并嘧啶
EP3012258A1 (en) Pyrazolo[1,5-a]pyrimidines and -triazines as antiviral agents
TW201726683A (zh) 作為ｈｉｖ整合酶抑制劑之稠合三環雜環化合物
CN112041307A (zh) 作为选择性雌激素受体降解剂的取代的苯并噻吩类似物
CN117940427A (zh) 作为cdk抑制剂的取代的吡唑并[1,5-a]嘧啶-7-胺化合物及其治疗用途
WO2021218997A1 (zh) 取代的氮杂五元环类化合物及其在药物中的应用
HK1231852B (en) Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as cdk inhibitors and their therapeutic use
HK1231852A1 (en) Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as cdk inhibitors and their therapeutic use
HK40063935A (zh) 多环tlr7/8拮抗剂及其在治疗免疫失调中的用途
MXPA06009245A (en) Pyrazolopyrimidine-derivatives as cyclin dependent kinase inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address

Address after: England Atsushi

Co-patentee after: British Emperor Innovation Co., Ltd.

Patentee after: IP2 IPO Innovation Co., Ltd.

Co-patentee after: Emory University

Address before: Great Britain

Co-patentee before: British Emperor Innovation Co., Ltd.

Patentee before: Cancer Research Technology Co., Ltd.

Co-patentee before: Emory University

CP03 Change of name, title or address